Financial

PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK

Solid Third-Quarter 2022 Revenues of $22.6 Billion Due to Exceptionally Strong Growth Achieved in the Prior-Year Quarter, Revenues Declined 2% Operationally Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 2% Operationally Third-Quarter 2022 Reported Diluted EPS(2) of $1.51, Reflecting 6% Growth Over Third-Quarter 2021, Including a $0.15 Incremental Benefit in the […]

EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS

IRVINE, Calif., Oct. 27, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2022. Third Quarter Highlights and Outlook Q3 sales of $1.32 billion grew 1 percent; constant currency1 sales grew 7 percent Q3 TAVR sales grew 1 percent; constant currency sales grew 6 percent Q3 EPS of $0.55; adjusted1 EPS […]

LeMaitre Q3 2022 Financial Results

BURLINGTON, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) — LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2022 results, announced a $0.125/share quarterly dividend and provided guidance. Q3 2022 Financial Results Sales of $39.0mm, +2% (+7% organic) vs. Q3 2021 Op. income $6.2mm, -32% Op. margin of […]

Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update

—ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 45% Year Over Year Growth for the Third Quarter of 2022 with Total Revenue of $67.7 Million, Marking the Strongest Quarter Since Launch— —Clinical Programs Progressing on Track; Company Expects to Complete Enrollment in Phase 3 ASPEN Trial of Brensocatib in First Quarter of 2023 and […]

Integer Holdings Corporation Reports Third Quarter 2022 Results

~ 3Q22 results in line with October 5, 2022 preliminary view ~ ~ Growth strategy fundamentals remain strong ~ PLANO, Texas, Oct. 27, 2022 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced results for the three months ended September 30, 2022. Third Quarter 2022 Highlights (compared […]

Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update

— U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway — — Commenced Launch of VAZKEPA® (icosapent ethyl) in England & Wales Mid-October As Planned – — Obtained Positive Scientific Assessment for Reimbursement in Italy and the Netherlands & Achieved Positive National Reimbursement in Finland […]

Acticor Biotech Announces Its 2022 Half-year Financial Results and Update on Its Clinical Progress

Significant clinical progress in the treatment of stroke with glenzocimab: Positive results from the ACTIMIS phase 1b/2a study Patent granted to protect glenzocimab in thrombotic diseases in Europe until 2036 Obtained “PRIME” status from the European Medicines Agency More than 150 patients enrolled to date in the ACTISAVE Phase 2/3 […]